Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses the United States experience of the Expanded Access Program (EAP) on radium-223 for prostate cancer.
Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer
January 17th 2025In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.
Read More